172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. (December 2022) - Papadopoulos, K.; Li, T.; Lakhani, N.; Powderly, J.; George, T.; Teoh, D.G.K.; Kilari, D.; Giaccone, G.; Sanborn, R.E.; Ghamande, S.; LoRusso, P.; Gibney, G.; et al.